Medical Conditions

Clesrovimab: New RSV Prevention for Infants

Editorially reviewed | Sources: CDC, AAP, NIH|Updated June 2026

The short answer

Clesrovimab is a long-acting monoclonal antibody being developed for the prevention of RSV (respiratory syncytial virus) lower respiratory tract disease in infants. Similar to nirsevimab (Beyfortus), it provides passive immunity against RSV by giving babies ready-made antibodies. This approach is especially important because RSV remains a leading cause of infant hospitalization, and infants under 6 months are too young for active vaccination. Consult your pediatrician about the latest RSV prevention options for your baby.

Thousands of parents search for this exact thing. You are not alone.

By Age

What to expect by age

0-3 months

Newborns and young infants are at highest risk for severe RSV disease. RSV monoclonal antibodies like clesrovimab are designed to be given as a single injection, typically before or during the RSV season, to provide protection for approximately 5 months. For babies born during RSV season (typically October through March in the Northern Hemisphere), the injection would ideally be given shortly after birth. This is particularly important for this age group, as they cannot receive active RSV vaccines.

3-6 months

Babies in this age range remain at significant risk for severe RSV. If your baby did not receive RSV immunoprophylaxis at birth, they may still be eligible for a dose before or during RSV season. The protection from monoclonal antibodies like clesrovimab provides coverage during the highest-risk period. Talk to your pediatrician about whether your baby should receive RSV prophylaxis, especially if they are entering their first RSV season.

6-24 months

While RSV risk decreases somewhat with age, children in their first two years are still vulnerable, especially those born prematurely, with chronic lung disease, or with congenital heart disease. RSV immunoprophylaxis recommendations may extend to older high-risk infants. As new products become available, the recommendations may evolve. Your pediatrician can advise whether RSV prophylaxis is recommended for your child based on their risk factors and the current season.

What Should You Do?

When to take action

Probably normal when...
  • Your baby received RSV prophylaxis (nirsevimab or clesrovimab) and has no adverse effects beyond mild injection site reactions.
  • Your baby goes through RSV season without developing significant respiratory illness after receiving prophylaxis.
  • Your pediatrician discusses RSV prevention options and recommends the best available option for your baby.
Mention at your next visit when...
  • You are unsure whether your baby has received RSV prophylaxis and RSV season is approaching.
  • Your baby has risk factors for severe RSV (prematurity, chronic lung disease, congenital heart disease) and you want to discuss prevention options.
  • You have questions about the difference between available RSV prevention products.
Act now when...
  • Your baby shows signs of RSV infection (wheezing, fast breathing, nasal flaring, poor feeding) regardless of whether they received prophylaxis.
  • Your baby develops a severe allergic reaction after receiving any RSV prophylaxis (difficulty breathing, facial swelling, widespread hives).
  • Your infant under 3 months develops any respiratory illness with breathing difficulty during RSV season.

Sources

Trust your instincts. If something feels wrong, reach out to your pediatrician.

Worrying about your baby means you care. That is a good thing.

RSV in Babies: What to Know

RSV (respiratory syncytial virus) is a common virus that affects nearly all children by age 2. Most babies have mild cold-like symptoms, but some, especially young infants and those with underlying conditions, can develop breathing difficulties. Watch for fast breathing, flaring nostrils, or visible chest pulling - these are signs to seek medical care.

Signs of Bronchiolitis in Babies

Bronchiolitis is a common lower respiratory infection in babies under 2 years, most often caused by RSV. It typically starts like a cold with runny nose and cough, then progresses to wheezing and breathing difficulty over 2-3 days. Most cases are mild and resolve at home within 1-2 weeks, but young infants (under 3 months) and babies born prematurely are at higher risk for severe illness requiring hospitalization.

Childhood Immunization Schedule: 2026 Updates

The childhood immunization schedule is reviewed and updated annually by the CDC's Advisory Committee on Immunization Practices (ACIP), the AAP, and the American Academy of Family Physicians. The schedule may include changes to timing, new vaccine recommendations, or updates to catch-up schedules. Always consult your pediatrician for the most current recommendations, as the schedule is designed to provide the earliest possible protection during the most vulnerable periods.

My Baby's Head Shape Looks Abnormal

Many babies develop temporary head shape irregularities that are completely normal. A cone-shaped head from vaginal delivery reshapes within days. Mild positional flattening (plagiocephaly) from sleeping on the back is very common and usually improves with repositioning and tummy time. However, head shape changes involving ridges, a persistently bulging fontanelle, or rapid head growth changes should be evaluated to rule out craniosynostosis.

Achondroplasia (Dwarfism) in Babies

Achondroplasia is the most common form of short-limbed dwarfism, affecting about 1 in 15,000 to 40,000 births. It is caused by a mutation in the FGFR3 gene and is usually apparent at birth with characteristic features including short limbs, a larger head, and a prominent forehead. Intelligence is normal. With monitoring for specific complications and supportive care, children with achondroplasia lead full, active, and independent lives.

Adenoid Hypertrophy and Breathing

Adenoids are lymphoid tissue located behind the nose that help fight infection in young children. When adenoids become enlarged (adenoid hypertrophy), they can block the nasal airway, causing chronic mouth breathing, snoring, nasal speech, and sleep-disordered breathing. Enlarged adenoids are most common between ages 2-7 and are a leading cause of obstructive sleep apnea in young children. Treatment ranges from watchful waiting and nasal steroids to surgical removal (adenoidectomy) if breathing or sleep is significantly affected.